Compare Sana Biotechnology Inc (SANA) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Xylem, Inc. — how do they compare? Sana Biotechnology Inc trades at $2.8 (market cap $836.71M), while Xylem, Inc. trades at $102.9 (market cap $23.81B). The key difference: Xylem, Inc. is far larger — about 28.5× Sana Biotechnology Inc's market cap, and Xylem, Inc. pays a 1.69% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Xylem, Inc. for 50 Days on average.
| SANA | XYL | |
|---|---|---|
Market Cap | $836.71M | $23.81B |
Volume | 4,507,444 | 2,234,713 |
Sector | Health | Industrials |
52-Week High | $5.92 | $152.95 |
52-Week Low | $2.68 | $100.92 |
Typical Hold Time | 23 Days | 50 Days |
Enterprise Value | $749.96M | $25.59B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Xylem (XYL) trades at $102.20, up 0.36% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results due October 27, 2026. Revenue grew to $9.04B in 2025, with a net income margin of 10.59%, while recent acquisitions like Cornell Pump and Roper Pump aim to strengthen its industrial water solutions presence.
The outlook is supported by steady revenue growth and margin expansion, but risks include China weakness and higher debt from recent note offerings. Analyst consensus is mixed with a $149.13 price target, suggesting potential upside, though technical indicators caution near-term pressure. Investment appeal hinges on execution of growth strategies amid competitive and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
